Kidney patients get closer to safer dosing of liver drug

NCT ID NCT06397872

Completed Knowledge-focused Sponsor: Madrigal Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how the drug resmetirom (Rezdiffra) is processed in the body of people with severe kidney impairment compared to healthy volunteers. 28 participants took a 100 mg pill once daily for 6 days. The goal was to measure drug levels and safety, not to treat any condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: resmetirom (Rezdiffra)
What this could lead to: If successful, this study could help doctors understand how to safely dose resmetirom in patients with severe kidney problems.
What could go wrong: This is a very early, small study (28 people) focused on drug levels, not on treating disease. It may not lead to any changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL IMPAIRMENT

Contacts and locations

Locations

Madrigal Research Center

Orlando, Florida, 32809, United States
Madrigal Research Center

Tampa, Florida, 33603, United States
Madrigal Research Center

Chicago, Illinois, 60643, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.